Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Met4.0
L-Methionin – Forschung
Überwiegend Mechanismus / Beobachtung
58 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu L-Methionin sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1975–2026 mit einer typischen Studiengröße von 132 Teilnehmenden.
Basierend auf 58 Studien · 13 Meta-Analysen · 29 RCTs · 66,420 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
1geholfen· 57 weitere ohne bewertete Effektdaten
Nach Outcome
Therapeutic & clinical
Überwiegend Mechanismus / Beobachtung19 Studien
Depression & mood
Überwiegend Mechanismus / Beobachtung17 Studien
Methylation & amino-acid metabolism
Überwiegend Mechanismus / Beobachtung13 Studien
Women's health
Überwiegend Mechanismus / Beobachtung6 Studien
Liver health
Überwiegend Mechanismus / Beobachtung4 Studien
InflammationRolle als Vorläufer für Methylierung/Entgiftung; keine Studien zeigen einen entzündungshemmenden Nutzen · 2-4 weeks
Überwiegend Mechanismus / Beobachtung4 Studien
Cognitive function
Überwiegend Mechanismus / Beobachtung3 Studien
Glucose & metabolic
Überwiegend Mechanismus / Beobachtung3 Studien
Heart & blood pressure
Zu wenige bewertete Studien2 Studien
Anxiety & stress
Zu wenige bewertete Studien1 Studie
Pain & analgesia
Zu wenige bewertete Studien1 Studie
Safety profile
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 17 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
100%
über Studien hinweg
Untersuchte Personen
66k
typische Studie: 132 Personen
Stärkste Designs
42
13 gepoolt, 29 randomisiert
Zeigte Nutzen
100%
1/1 Studien
Wie lange Studien liefen
1–3 Monate
1
3+ Monate
1
Untersuchte Populationen
Patients with depression2
General population2
Patients with chronic liver disease1
MDD patients1
Aktives Forschungsgebiet
27 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
197520002026
1Depression symptoms reliefMeta-Analysen=1,522 · large study2024
Einfach gesagt: SAMe may provide relief of depression symptoms similar to imipramine or escitalopram.
Peng TR et al. · General hospital psychiatry (2024)
SAMe may provide relief of depression symptoms similar to imipramine or escitalopram.
However, the results of the comparisons should be interpreted with caution due to the small number of studies and the large range of SAMe doses that were used in the included trials.
Therefore, we recommend that patients discuss treatment options with their doctor before taking SAMe.
2Treatment of chronic liver diseaseMeta-Analysen=705 · large study2015
Einfach gesagt: However, SAMe also demonstrated limited clinical value in the treatment of certain chronic liver diseases.
Guo T et al. · PloS one (2015)
In a subgroup analysis of gravidas and children, several of the included data indicated that there was a significant difference in the pruritus score.
Furthermore, the results regarding ursodeoxycholic acid (UDCA) and stronger neo-minophagen C (SNMC) indicated that both treatments were more effective than SAMe was in certain chronic liver diseases.
These findings suggest that SAMe could be used as the basis of a medication regimen for liver function improvement because of its safety.
5Peripheral blood metabolites in major depressive disorderMeta-Analysen=46 · small study2021
Einfach gesagt: MDD patients were characterized by higher levels of asymmetric dimethylarginine, tyramine, 2-hydroxybutyric acid, phosphatidylcholine (32:1), and taurochenodesoxycholic acid and lower levels of L-acetylcarnitine, creatinine, L-asparagine, L-glutamine, linoleic acid, pyruvic acid, palmitoleic acid, L-serine, oleic acid, myo-inositol, dodecanoic acid, L-methionine, hypoxanthine, palmitic acid, L-tryptophan, kynurenic acid, taurine, and 25-hydroxyvitamin D compared with controls.
Pu J et al. · Molecular psychiatry (2021)
Pathway and network analyses revealed altered amino acid metabolism and lipid metabolism, especially for the tryptophan-kynurenine pathway and fatty acid metabolism, in the peripheral system of MDD patients.
Our findings may facilitate biomarker development and the elucidation of the molecular mechanisms that underly MDD.
Einfach gesagt: Moderate-certainty evidence suggests that SAMe monotherapy may offer a moderate therapeutic benefit in alleviating depressive symptoms.
Limveeraprajak N et al. · Progress in neuro-psychopharmacology & biological psychiatry (2024)
Moderate-certainty evidence suggests that SAMe monotherapy may offer a moderate therapeutic benefit in alleviating depressive symptoms.
Considering its favorable acceptability profile, SAMe monotherapy should be considered as a treatment option for patients with depression.
However, uncertainties regarding its efficacy as an adjunct to AD and its comparative efficacy with ADs remain unresolved.
Einfach gesagt: No recommendations were made when the evidence was low quality or trade-offs were so closely balanced that any recommendation would be too speculative.
Crawford C et al. · Pain medicine (Malden, Mass.) (2019)
No recommendations were made when the evidence was low quality or trade-offs were so closely balanced that any recommendation would be too speculative.
Research recommendations are provided to enhance the quality and body of evidence for the most promising ingredients.
Clinicians and those with chronic pain can rely on evidence-based recommendations to inform their decisions.
Einfach gesagt: However, there is currently a paucity of high-quality data regarding the use of add-on treatments in patients with MDD who are inadequate responders to antidepressants, with quetiapine XR presenting the most comprehensive evidence base to date.
Turner P et al. · Journal of psychopharmacology (Oxford, England) (2014)
Comparison of the different drug classes indicated that most interventions had similar efficacy.
The likelihood of response was significantly greater with SAMe versus placebo and lithium and with quetiapine XR versus placebo.
Most add-on interventions demonstrated comparable efficacy in patients with MDD and an inadequate response to initial antidepressants.
Einfach gesagt: Currently the scientific evidence is insufficiently robust to establish definitive clinical practice guidelines, but processes could be established to track the impact of these ingredients.
Crawford C et al. · Pain medicine (Malden, Mass.) (2019)
Currently the scientific evidence is insufficiently robust to establish definitive clinical practice guidelines, but processes could be established to track the impact of these ingredients.
Until then, providers have the evidence needed to make informed decisions about the safe use of these dietary ingredients, and future research can address existing gaps.
13Systematische Übersichtn=14 · very small study2021
Einfach gesagt: The methodological shortcoming of existing studies and directions for future research are discussed to facilitate high-quality research in this evolving area of nutritional psychiatry.
Qureshi FM et al. · Aggressive behavior (2021)
Out of the 14 studies, 5 reported a beneficial effect of nutritional supplementation (omega-3 fatty acids, vitamins/minerals, S-adenosyl-l-methionine, or tryptophan).
The results overall indicated that research in this area is in its infancy: very few studies examined the same composition of nutritional supplementation and when they did so the results were contradictory.
The methodological shortcoming of existing studies and directions for future research are discussed to facilitate high-quality research in this evolving area of nutritional psychiatry.
14hypertension riskMeta-Analysen=57,913 · very large study2025
Einfach gesagt: Future research with standardized methodologies is needed to confirm these associations and inform clinical and public health guidance.
Izadi N, Hadi R, Shafiee A, Fathi H, Niknam M, Amiri P. · BMC public health (2025)
Groß Nutzen
← SchlechterKein EffektBesser →
Prospectively, higher intake of branched-chain amino acids significantly increased the hazard of hypertension.
Conversely, glycine intake was consistently associated with a protective effect (pooled OR = 0.75; 95% CI: 0.64-0.89).
Conclusion Specific dietary amino acids have distinct associations with HTN risk.
Du H, Hu Y, Ye H, Di S, Yan H. · Frontiers in endocrinology (2026)
Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were synthesized using a random-effects model accounting for the potential influence of heterogeneity.
Overall, HHcy was significantly associated with uRPL (OR 3.46, 95% CI 2.33-5.14; I² = 57%).
The association was stronger in studies with Hcy cutoff > 12 μmol/L compared to ≤ 12 μmol/L (OR 4.02 vs. 2.00; p = 0.02), and in studies using HPLC or immunoassay compared with enzymatic methods (OR 3.59 and 4.53 vs. 1.84; p = 0.02).
16Depression treatment outcomesMeta-Analysen=185 · medium study2010
Einfach gesagt: Participants in CAM trials were more likely to be female and to have a lower placebo-response rate compared to those in standard antidepressant trials for MDD.
Freeman MP et al. · The Journal of clinical psychiatry (2010)
Participants in CAM trials were more likely to be female and to have a lower placebo-response rate compared to those in standard antidepressant trials for MDD.
Trials of standard antidepressants and CAM therapies were composed of patients with similar depression severity.
Einfach gesagt: Therefore, ursodeoxycholic acid, pirfenidone, S-adenosyl-L-methionine, and N-acetylcysteine could represent therapeutic strategies for the treatment of liver pathologies.
Muriel P et al. · International journal of molecular sciences (2026)
N-acetylcysteine (NAC) is a precursor to L-cysteine and GSH and is used in clinical settings to treat cancer, nephropathy, heart disease, pulmonary fibrosis, polycystic ovary syndrome, and influenza.
Regarding the liver, NAC is the most accepted treatment for DILI, especially after paracetamol overdose.
Owing to its antioxidant and anti-inflammatory actions, NAC has been successfully used to treat chronic liver injuries, including hepatosteatosis and fibrosis.
18Antioxidant treatment effectiveness for ALSSystematische Übersichtn=23 · very small study2008
Einfach gesagt: While there is no substantial clinical trial evidence to support their clinical use, there is no clear contraindication.
Orrell RW et al. · Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases (2008)
Further well-designed trials of medications such as vitamin C and E are unlikely to be performed.
If future trials of antioxidant medications are performed, careful attention should be given to sample size, outcome measures, and duration of the trial.
The high tolerance and safety, and relatively low cost of vitamins C and E, and other considerations related to the lack of other effective treatments for amyotrophic lateral sclerosis, explain the continuing use of these vitamins by physicians and people with amyotrophic lateral sclerosis.
19Subclinical depression symptomsRCTn=140 · medium study2023
Einfach gesagt: Conclusions: The received results confirm the available evidence for the properties of SAMe in depression and complement them with evidence of the ef-fectiveness of the Deprilium® complex that contains SAMe and L-methylfolate with methylcobalamin, which together produce pharmacological and clinical synergy to reduce the severity of subclinical depressive manifestations in patients with NCD.
Results: After 60 days a statistically significant difference was observed in all clinical indicators between the intervention group and the control group.
When comparing the indicators of the intervention group on the 1st and on the 60th day of the study, statistically significant changes (p <0.000) were observed in all three indicators.
Further studies of the effectiveness of the use of the Deprilium® complex in patients with NCD are required.